DataM Intelligence Releases Pharmaceutical Competitive Analysis Reports
DataM Intelligence has launched a series of competitive intelligence reports focusing on the pharmaceutical sector. The reports offer market insights and analysis across various therapeutic areas.
DataM Intelligence, a market research firm, has expanded its offerings with new competitive intelligence reports covering multiple therapeutic areas within the pharmaceutical industry. The "Strategic Insights" reports are designed to provide data-driven decision support for professionals in the sector.
Released in June 2025, the analyses delve into market dynamics and competitive landscapes. For instance, a report on Ankylosing Spondylitis (AS) highlights the impact of biosimilars on pricing while emphasizing the strategic value driven by innovation. Another report examines the market for IgG4-Related Disease (IgG4-RD), noting UPLIZNA's leading position amidst a race for innovation among competitors.
Other areas covered include Uveal Melanoma, Generalized Anxiety Disorder (GAD), Chronic Rhinosinusitis with Nasal Polyps, and Diabetic Retinopathy (DR). The company states that these reports offer expert-curated strategies, market foresight, and deep competitive analysis. DataM Intelligence provides access to its entire database through a subscription model.
The firm's coverage extends across numerous therapeutic fields such as Allergy & Respiratory, Cardiology, Dermatology, Endocrinology, Gastroenterology, Hematology, Infectious Disease, Musculoskeletal, Neurology, Oncology, Ophthalmology, Rare Diseases, Urology, Biosimilars, and Vaccines. The company also monitors developments in Cell & Gene Therapy.